Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Withdrawal of Voxelotor: Implications for Clinical Practice in Sickl…

Akshat Jain

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Medical Jeopardy: 2024 Update

Scripps Health

J. Diamant

ACP 2024 Insights: Sickle Cell Anemia - Diagnosis and Management of …

Insights from 2024 ACP Annual Meeting

M. Okam Achebe

Highlights in Red Cell and Platelet Disorders From ASH 2023

Insights from 2023 ASH Annual Meeting

M. Blinder

Role of Antiplatelet and Anticoagulant Therapy: Managing Vaso-Occlus…

Erica Sparkenbaugh

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Peslak

Outcomes of Lovo-Cel Gene Therapy in Sickle Cell Disease: 60-Month F…

Yale Cancer Center

J. Ryu

Recent Gene Therapy Approvals in SCD: Clinical and Logistical Consid…

Nirmish Shah

A Guide for Shared Decision Making in Sickle Cell Disease

UCSF School of Medicine

M. Treadwell

Gene Therapy for Sickle Cell Disease: Are We Where They Wanted Us to…

Cayenne Wellness 15th Annual Hybrid Sickle Cell Disease Educational Summit

A. Sharma

Conference Highlights: Opioids in Medically Complex Patients - Old C…

2024 Conference Highlights

A. Mishkin

Management of Patients with Sickle Cell Anemia, Hospitalist Edition

Duke Health

R. Doshi

Managing the Benign Hematology Consult: Treatment Recommendations fo…

Indy Hematology Review

C. Kessler

Sickle Cell Disease 101

Cayenne Wellness 15th Annual Hybrid Sickle Cell Disease Educational Summit

I. Osunkwo

Stroke and Transcranial Doppler in Congolese SCD

Leon Tshilolo

ASH 2023 Summary: "Updates in Hereditary TTP and Sickle Cell Disease"

BMFcases

I. Ibrahim, T. Bat, Y. Shen

Breakthroughs in the Care of Sickle Cell Disease

Yale Cancer Center

C. Calhoun, E. Winer